by Biotechnology has moved far beyond traditional laboratory research. Today, it sits at the center of some of healthcare’s biggest developments from biologics and vaccines to gene editing, cell and gene therapies, genomics, and personalized medicine.
As scientific innovation accelerates, several companies are building strong positions through research, advanced technologies, strategic partnerships, and expanding product pipelines.
According to Towards Healthcare, the global biotechnology sector is projected to reach USD 5,666.02 billion by 2035, growing at a 12.5% CAGR from 2026 to 2035. North America currently leads the sector, supported by strong research infrastructure, investment, and biotechnology innovation.
So, who are the major players shaping the biotechnology field today?
Request Exclusive Report Preview : https://www.towardshealthcare.com/download-sample/5034
Leading Biotechnology Companies
Towards Healthcare identifies Lonza, AstraZeneca, Pfizer, Gilead Sciences, Roche, Biogen, Celgene, Sanofi, Abbott, and Novartis among the top key players in the global biotechnology landscape.
1. Lonza
Lonza has an important role in biotechnology manufacturing and development, particularly through its CDMO capabilities. Its services support biopharmaceutical companies across development, manufacturing, and advanced therapies.
The company’s position also reflects the growing importance of outsourcing as biotechnology companies look for specialized manufacturing infrastructure and expertise.
2. AstraZeneca
AstraZeneca is another major biotechnology and biopharmaceutical player, with a broad focus on areas including oncology, rare diseases, cardiovascular and metabolic conditions, and respiratory diseases.
Towards Healthcare identifies AstraZeneca among the strategic companies shaping the global biotechnology landscape.
3. Pfizer
Pfizer continues to play a significant role across biotechnology and biopharmaceutical development, including vaccines, biologics, oncology, and advanced therapeutic platforms.
Towards Healthcare also highlights Pfizer’s biotechnology pipeline and its growing focus on cancer therapies, including antibody-drug conjugates and bispecific antibodies.
4. Gilead Sciences
Gilead Sciences has built a strong biotechnology presence across antiviral medicines, oncology, and cell therapy.
Its acquisition of Kite Pharma has also strengthened its position in CAR-T and T-cell receptor therapies, making Gilead an important participant in the rapidly evolving cell and gene therapy ecosystem.
5. Roche
Roche is a major biotechnology and biotherapeutics company with strong capabilities in biologics and oncology.
Towards Healthcare identifies Roche as a Tier 1 company in the biotherapeutics landscape, highlighting its position in biologic medicines and oncology therapies.
6. Biogen
Biogen is another established biotechnology company included among Towards Healthcare’s leading biotechnology players.
Its focus on innovative therapies has helped maintain its position within the biotechnology ecosystem.
7. Sanofi
Sanofi has a significant presence in biologics and biotechnology-driven therapeutic development, including immunology and vaccines.
Towards Healthcare identifies Sanofi among the leading companies contributing to the global biotechnology and biological therapies landscape.
8. Abbott
Abbott brings biotechnology capabilities together with diagnostics, medical devices, nutrition, and healthcare technologies.
Its broad healthcare portfolio gives the company an important position across several parts of the biotechnology and life sciences ecosystem.
9. Novartis
Novartis is another major biotechnology and biopharmaceutical company, with increasing involvement in advanced therapeutic platforms.
Towards Healthcare highlights its presence in gene therapy, CAR-T therapy, xRNA, radioligand therapy, and cell and gene therapy.
10. Celgene
Celgene is also listed by Towards Healthcare among the key biotechnology companies. Its legacy in innovative therapies, particularly in oncology and hematology, contributes to its recognition within the biotechnology landscape.
Biotechnology Is More Than Drug Development
One of the most interesting aspects of biotechnology today is the breadth of technologies involved.
The industry increasingly brings together:
- Genomics
- Gene editing
- Cell and gene therapy
- Biologics
- Synthetic biology
- mRNA technologies
- Personalized medicine
- AI-driven drug discovery
- Advanced biomanufacturing
- Precision diagnostics
Towards Healthcare specifically identifies AI, gene editing, synthetic biology, and advanced drug discovery tools as important trends shaping biotechnology.
This means competition is no longer limited to traditional pharmaceutical companies. Technology providers, CDMOs, research organizations, and specialized biotechnology companies are becoming increasingly important.
The Growing Role of Biotechnology Manufacturing
Scientific discovery is only one part of the equation. Once a promising therapy moves toward clinical development and commercialization, companies need reliable manufacturing capabilities.
Towards Healthcare estimates that the global biotechnology CMO and CDMO sector will reach approximately USD 220.60 billion by 2035, growing at a CAGR of 11.54% from 2026 to 2035.
Leading providers include Thermo Fisher Scientific, Lonza, Boehringer Ingelheim BioXcellence, Rentschler Biopharma, AGC Biologics, AbbVie Contract Manufacturing, KBI Biopharma, and Charles River Laboratories, among others.
This highlights an important shift: biotechnology companies increasingly depend on specialized partners to move therapies from the laboratory into scalable production.
Cell and Gene Therapy Is Reshaping Biotechnology
Cell and gene therapy is one of the strongest examples of how biotechnology is changing healthcare.
Companies such as Gilead Sciences/Kite, Novartis, Johnson & Johnson/Legend Biotech, Bristol Myers Squibb, Amgen, and Biogen are increasingly involved in advanced therapies, including CAR-T, gene editing, and viral gene therapy.
The growth of these therapies is also creating demand for specialized manufacturing, testing, logistics, and supply-chain solutions.
What Is Driving Biotechnology Growth?
Several forces are supporting the continued expansion of biotechnology:
Increasing R&D Investment
Biotechnology companies are attracting significant investment as researchers pursue new therapeutic approaches and technologies. Towards Healthcare reports that approximately USD 26 billion was raised through biotechnology venture capital rounds in 2024.
Growth of Personalized Medicine
Advances in genomics and molecular diagnostics are enabling treatments to become increasingly targeted to individual patient characteristics.
Expansion of Biologics
Biologics continue to represent a major area of pharmaceutical innovation, creating opportunities for biotechnology companies and specialized manufacturing providers.
Advancements in Gene Editing
Technologies such as CRISPR are opening new possibilities for treating genetic and other complex diseases.
AI and Drug Discovery
Artificial intelligence is increasingly being integrated into research workflows to analyze complex biological data and accelerate the identification of potential drug candidates.
Who Will Shape the Next Phase of Biotechnology?
The biotechnology landscape is becoming more collaborative.
Large biopharmaceutical companies are working with emerging biotechnology firms, technology providers, academic institutions, and CDMOs to accelerate innovation.
At the same time, smaller biotech companies are increasingly attracting funding and partnerships to move specialized therapies through clinical development.
This creates an ecosystem where innovation, manufacturing, data, partnerships, and commercialization are becoming equally important.
Get smarter healthcare insights with our dedicated Ecosystem Dashboard.
https://www.towardshealthcare.com/access-dashboard
Insights from Payal Rabde – bringing a strategic perspective to evolving healthcare trends and developments.
About Us
Pharma Geek is a part of Towards Healthcare Research & Consulting which is a global healthcare market research and consulting firm dedicated to helping businesses make informed decisions through reliable market intelligence and strategic insights. We serve pharmaceutical, biotechnology, medical device, AI in healthcare, cell and gene therapy, digital health, and life sciences organizations with in-depth market research, custom consulting, competitive analysis, and growth forecasts. Our team combines industry expertise with rigorous research to deliver clear, actionable insights that support market expansion, product strategy, investment decisions, and long-term business growth. From emerging innovations to established healthcare markets, we help organizations understand where the industry is today and where it’s headed tomorrow.
You can place an order or ask any questions, please feel free to contact us at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: Towards Healthcare Research & Consulting – Expert Consulting Solutions & Research Reports
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium
